Physician profile
Michael S Alexander
NPI 1649352261
$8,448.52
in general payments reported to CMS, 2019-2025
46 companies · $1,693 in 2025
The $1,693 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,699 · 2020: $1,047 · 2021: $1,585 · 2022: $584 · 2023: $802 · 2024: $1,040 · 2025: $1,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,535.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,209.81 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $725.96 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $721.20 | 2019-2025 | |
| Novo Nordisk INC | $675.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $500.18 | 2021-2025 | Qulipta, Vraylar |
| Amgen INC. | $434.09 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $371.40 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $333.99 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $306.75 | 2019-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $265.44 | 2019-2025 | |
| Astellas Pharma US INC | $262.67 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $229.98 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.15 | 2019-2023 | Trulance, Xifaxan |
| Allergan, INC. | $210.89 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.59 | 2019-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.